- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2018
- Public Summary Document (PSD) July 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2018 PBAC Meeting - Word
Pembrolizumab (nsclc) – July 2018
Pembrolizumab (NSCLC): Powder for injection 50 mg; Solution concentrate for I.V. infusion 100 mg in
Last updated
26 October 2018